HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial – The Cancer Letter
Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer. To access this subscriber-only content please log in or […]